CAS 76263-13-3
:Fluzinamide
- Fluzinamide [USAN:INN]
- 1-Azetidinecarboxamide, N-methyl-3-(3-(trifluoromethyl)phenoxy)-
- Ahr 8559
- Fluzinamida
- Fluzinamida [Spanish]
- Fluzinamidum
- Fluzinamidum [Latin]
- N-Methyl-3-((alpha,alpha,alpha-trifluoro-m-tolyl)oxy)-1-azetidinecarboxamide
- Unii-Iaf7F741Sx
- N-methyl-3-[3-(trifluoromethyl)phenoxy]azetidine-1-carboxamide
Fluzinamide
CAS :Fluzinamide is a growth regulator that is typically used to treat epilepsy and other neurological disorders. It has been shown to be effective in the treatment of certain types of epilepsy, such as partial seizures, generalized tonic-clonic seizures, and mixed seizure patterns. Fluzinamide is administered orally or by injection and can be reconstituted with sterile water for intravenous administration. The plasma concentration of fluzinamide is higher than its serum concentration because it is highly protein bound. Fluzinamide is metabolized by conjugation with fatty acids and fatty acid metabolites. These metabolites are excreted through the urine and bile after conjugation with glucuronic acid. Fluzinamide also binds to diagnostic agents such as radioactive iodine or technetium-99m, allowing them to bind to thyroid tissue in order to image the gland for treatment purposes. The terminal half-life of fluzinamide ranges from 18 hours (4 hours when given intravenously
Formule :C12H13F3N2O2Degré de pureté :Min. 95%Masse moléculaire :274.24 g/molFluzinamide
CAS :Fluzinamide (AHR-8559) has anticonvulsant effects on ignited amygdala seizures.Formule :C12H13F3N2O2Degré de pureté :99.38% - >99.99%Couleur et forme :SolidMasse moléculaire :274.24


